Epidemiological data on the use of traditional anticoagulants in cardiovascular disease

Epidemiological data on the use of traditional anticoagulants in cardiovascular disease

Dettagli Bibliografici
Autori principali:	Reith, C, Baigent, C
Altri autori:	DeCaterina, R
Natura:	Book section
Pubblicazione:	Oxford University Press 2018

Documenti analoghi

Role of aspirin in primary prevention of cardiovascular disease
di: Patrono, C, et al.
Pubblicazione: (2019)

Clinical effects of anticoagulants in suspected acute myocardial infarction - Reply
di: Collins, R, et al.
Pubblicazione: (1997)

Coxibs, traditional NSAIDs and cardiovascular safety post-PRECISION: What we thought we knew then and what we think we know now
di: Patrono, C, et al.
Pubblicazione: (2017)

Renal function: an emerging risk factor for cardiovascular disease?
di: Landray, M, et al.
Pubblicazione: (2001)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
di: Schlackow, I, et al.
Pubblicazione: (2017)

Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal.
di: Baigent, C, et al.
Pubblicazione: (2003)

Anticoagulants in heart disease: current status and perspectives.
di: De Caterina, R, et al.
Pubblicazione: (2007)

Which cardiovascular risk factors matter in chronic kidney disease?
di: Baigent, C, et al.
Pubblicazione: (2007)

Premature cardiovascular disease in chronic renal failure.
di: Baigent, C, et al.
Pubblicazione: (2000)

Use of Bivalirudin for Anticoagulation in Interventional Cardiovascular Procedures
di: Zhen Ge, et al.
Pubblicazione: (2018-06-01)

Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis.
di: Hennekens, C, et al.
Pubblicazione: (2006)

The Epidemiology of Cardiovascular Disease
di: Hobbs, R, et al.
Pubblicazione: (2009)

Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?
di: Preiss, D, et al.
Pubblicazione: (2017)

Benefits of lowering cholesterol in chronic kidney disease Reply
di: Baigent, C, et al.
Pubblicazione: (2011)

Angiotensin receptor blockers and β-blockers in Marfan syndrome: an individual-patient-data meta-analysis of randomised trials
di: Pitcher, A, et al.
Pubblicazione: (2022)

Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure?
di: Baigent, C, et al.
Pubblicazione: (2000)

Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment.
di: Landray, M, et al.
Pubblicazione: (2001)

Epidemiology of cardiovascular disease in Europe
di: Wright, F
Pubblicazione: (2021)

Anticoagulation regimes and their influence on the occlusion rate of aneurysms: an experimental study in rabbits.
di: Grunwald, I, et al.
Pubblicazione: (2005)

Traditional and Non-traditional Cardiovascular Risk Factors and Cardiovascular Disease in Women with Psoriasis
di: Charlotte Näslund-Koch, et al.
Pubblicazione: (2022-10-01)

Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease.
di: De Caterina, R, et al.
Pubblicazione: (2013)

Deaths from cardiovascular disease involving anticoagulants: a systematic synthesis of coroners' case reports
di: Anis, A, et al.
Pubblicazione: (2022)

Deaths from cardiovascular disease involving anticoagulants: a systematic synthesis of coroners’ case reports
di: Ali Anis, et al.
Pubblicazione: (2022-03-01)

The urgent need for a policy on epidemiological data on cardiovascular diseases in Bangladesh
di: Amrin Yeasin Proma, et al.
Pubblicazione: (2023-07-01)

Editorial: Anticoagulation in cardiovascular diseases: evolving role, unmet needs, and grey areas
di: Antonino Tuttolomondo, et al.
Pubblicazione: (2023-10-01)

Traditional Chinese Medicine Is Widely Used for Cardiovascular Disease
di: Dan Hu, et al.
Pubblicazione: (2018-04-01)

General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
di: De Caterina, R, et al.
Pubblicazione: (2013)

Statins for people at low risk of cardiovascular disease reply
di: Mihaylova, B, et al.
Pubblicazione: (2012)

Cardiovascular disease in Europe: epidemiological update.
di: Nichols, M, et al.
Pubblicazione: (2013)

Epidemiological Features of Cardiovascular Disease in Asia
di: Dong Zhao, MD, PhD
Pubblicazione: (2021-06-01)

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.
di: De Caterina, R, et al.
Pubblicazione: (2012)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
di: Herrington, W, et al.
Pubblicazione: (2016)

SURGICAL TREATMENT OF HEMORRHOIDAL BLEEDING IN PATIENTS WITH CARDIOVASCULAR DISEASES UNDER ANTICOAGULANT AND ANTIPLATELET THERAPY
di: A. Z. Tsitskarava, et al.
Pubblicazione: (2019-12-01)

Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review
di: Xiulin Xiao M.S., et al.
Pubblicazione: (2024-11-01)

Cancer and cardiovascular disease after vasectomy: an epidemiological database study.
di: Goldacre, M, et al.
Pubblicazione: (2005)

Atrial Fibrillation and Risk of Dementia: Epidemiology, Mechanisms, and Effect of Anticoagulation
di: Rose Mary Ferreira Lisboa Da Silva, et al.
Pubblicazione: (2019-01-01)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
di: Storey, B, et al.
Pubblicazione: (2017)

Coxibs and traditional NSAIDs for pain relief - Authors' reply.
di: Bhala, N, et al.
Pubblicazione: (2014)

Trends in the epidemiology of cardiovascular disease in the United Kingdom
di: Bhatnagar, P, et al.
Pubblicazione: (2016)

Cardiovascular disease in Europe 2014: epidemiological update.
di: Nichols, M, et al.
Pubblicazione: (2014)